Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

PBMs Eye Acquisitions In “Target-Rich Environment”

  • News

Executive Summary

Medco could seek to grow through acquisitions that cost less than $300 mil

You may also be interested in...



Zocor, Zoloft And Pravachol Will Be Key Generic Switches For Medco In ’06

Medco sees a significant opportunity for growth in 2006 generic switches, Group President-National Accounts Timothy Wentworth says

Zocor, Zoloft And Pravachol Will Be Key Generic Switches For Medco In ’06

Medco sees a significant opportunity for growth in 2006 generic switches, Group President-National Accounts Timothy Wentworth says

Medco Says It Is Ready For Part D: Will CMS Be?

Medco is "leaning" toward participating directly in the Medicare Part D stand-alone prescription drug insurance program in 2006, CEO David Snow said during an analyst meeting Nov. 11 in Philadelphia

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS045069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By